GleamWall
中文EN

LENZ LENZ Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1815776 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-29.4%
TTM net income YoY-138.2%
TTM EPS YoY-119.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin82.0%
Operating margin-1,211.2%
Net margin-1,135.0%
FCF margin-1,033.3%
EBITDA margin-1,207.6%

Returns

ROE-72.7%
ROA-66.7%
ROIC (approx.)-71.7%
Asset turnover0.06x

Leverage & solvency

Liabilities / assets8.5%
Debt / equity0.00x
Current ratio11.66x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.91x
Accruals ratio-6.0%
Payout ratio—
Capex / revenue0.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$19.09M$0
Cost of revenue$418,000$0
Gross profit$18.67M$0
R&D expense$18.67M$29.80M
SG&A expense$91.14M$28.81M
Operating income-$91.14M-$58.61M
Pretax income-$81.62M-$49.77M
Income tax$502,000$1,000
Net income-$82.13M-$49.77M
EBITDA-$90.85M-$58.55M
EPS (basic)-2.85-2.34
EPS (diluted)-2.85-2.34
Weighted avg. shares (diluted)28.81M21.28M
Balance sheet
Cash & equivalents$25.18M$20.16M
Receivables$329,000$0
Inventory$2.94M$0
Current assets$301.41M$211.92M
PP&E, net$1.19M$651,000
Total assets$305.88M$215.30M
Current liabilities$21.19M$10.41M
Total liabilities$21.54M$11.22M
Shareholders' equity$284.34M$204.08M
Shares outstanding31.34M27.52M
Cash flow statement
Operating cash flow-$69.17M-$59.39M
Capital expenditure$827,000$468,000
Free cash flow-$70.00M-$59.86M
Investing cash flow-$75.67M-$154.48M
Financing cash flow$149.75M$199.00M
Depreciation & amortization$287,000$58,000
Stock-based compensation$12.55M$6.37M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.